NCT00660452View on ClinicalTrials.gov

A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites

PHASE3CompletedINTERVENTIONAL
Enrollment

484

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Allergy
Interventions
DRUG

Staloral

Sublingual immunotherapy with Staloral dust mites solution

Trial Locations (1)

100029

Peking Union Medical College Hospital -, Beijing

Sponsors

Lead Sponsor

Stallergenes Greer
All Listed Sponsors
lead

Stallergenes Greer

INDUSTRY

NCT00660452 - A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites | Biotech Hunter | Biotech Hunter